Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169:1053.

Article  PubMed  PubMed Central  Google Scholar 

Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, et al. Natural history of Crohnʼs disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953–61.

Article  PubMed  Google Scholar 

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology. 2007;132:863–73.

Article  PubMed  CAS  Google Scholar 

Hyams J, Damaraju L, Blank M, Johanns J, Guzzo C, Winter HS, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol. 2012;10:391-9.e1.

Article  PubMed  CAS  Google Scholar 

Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA, Colletti RB, et al. Safety and efficacy of adalimumab for moderate to severe Crohn’s disease in children. Gastroenterology. 2012;143:365-74.e2.

Article  PubMed  CAS  Google Scholar 

Faubion WA, Dubinsky M, Ruemmele FM, Escher J, Rosh J, Hyams JS, et al. Long-term efficacy and safety of adalimumab in pediatric patients with Crohnʼs Disease. Inflamm Bowel Dis. 2017;23:453–60.

Article  PubMed  Google Scholar 

Croft NM, Faubion WA, Kugathasan S, Kierkus J, Ruemmele FM, Shimizu T, et al. Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study. Lancet Gastroenterol Hepatol. 2021;6:616–27.

Article  PubMed  Google Scholar 

Farr R, Karam L, Kitagawa S, Kellermayer R. Infliximab can be effective in pediatric patients with ulcerative colitis and primary failure of adalimumab. Ann Clin Lab Sci. 2022;52:796–801.

PubMed  CAS  Google Scholar 

Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, et al. Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian society of pediatric gastroenterology, hepatology, and nutrition experience. BTT. 2019;13:13–21.

Article  CAS  Google Scholar 

Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157–67.

Article  PubMed  CAS  Google Scholar 

Martinez-Vinson C, Lemoine A, Bouhnik Y, Braithwaite B, Fohlen-Weill A, Addison J. PERFUSE: non-interventional cohort study of patients receiving infliximab biosimilar sb2: results in pediatric patients. J Pediatr Gastroenterol Nutr. 2023;76:451–9.

Article  PubMed  CAS  Google Scholar 

Dipasquale V, Pellegrino S, Ventimiglia M, Cucinotta U, Citrano M, Graziano F, et al. Real-life experience of infliximab biosimilar in pediatric-onset inflammatory bowel disease: data from the sicilian network for inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2022;34:1007–14.

PubMed  CAS  Google Scholar 

Richmond L, Curtis L, Garrick V, Rogers P, Wilson M, Tayler R, et al. Biosimilar infliximab use in paediatric IBD. Arch Dis Child. 2018;103:89–91.

Article  PubMed  Google Scholar 

Gervais L, McLean LL, Wilson ML, Cameron C, Curtis L, Garrick V, et al. Switching from originator to biosimilar infliximab in paediatric inflammatory bowel disease is feasible and uneventful. J pediatr gastroenterol nutr. 2018;67:745–8.

Article  PubMed  CAS  Google Scholar 

Chanchlani N, Mortier K, Williams LJ, Muhammed R, Auth MKH, Cosgrove M, et al. Use of infliximab biosimilar versus originator in a pediatric united kingdom inflammatory bowel disease induction cohort. J Pediatr Gastroenterol Nutr. 2018;67:513–9.

Article  PubMed  CAS  Google Scholar 

Nikkonen A, Kolho K. Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease. Acta Paediatr. 2020;109:836–41.

Article  PubMed  CAS  Google Scholar 

McClinchie MG, Lakhani A, Abdel-Rasoul M, McNicol M, Shkhkhalil AK, Boyle BB, et al. Similar growth outcomes in children with inflammatory bowel disease initiated on infliximab originator or biosimilar. J Pediatr Gastroenterol Nutr. 2023;77:499–504.

Article  PubMed  CAS  Google Scholar 

Dipasquale V, Alibrandi A, Pellegrino S, Ramistella V, Romano C. Factors that influence infliximab biosimilar trough levels in the pediatric inflammatory bowel disease population. Expert Rev Clin Immunol. 2024;20:237–44.

Article  PubMed  CAS  Google Scholar 

Sieczkowska-Golub J, Meglicka M, Plocek A, Banaszkiewicz A, Jarzębicka D, Toporowska-Kowalska E, et al. Induction therapy with biosimilar infliximab in children with Crohn disease. J Pediatr Gastroenterol Nutr. 2017;65:285–8.

Article  PubMed  CAS  Google Scholar 

Cheon JH, Nah S, Kang HW, Lim YJ, Lee SH, Lee SJ, et al. Infliximab biosimilar CT-P13 observational studies for rheumatoid arthritis, inflammatory bowel diseases, and ankylosing spondylitis: pooled analysis of long-term safety and effectiveness. Adv Ther. 2021;38:4366–87.

Article  PubMed  CAS  Google Scholar 

Gianolio L, Armstrong K, Swann E, Shepherd R, Henderson P, Wilson DC, et al. Effectiveness of switching to subcutaneous infliximab in pediatric inflammatory bowel disease patients on intravenous maintenance therapy. J Pediatr Gastroenterol Nutr. 2023;77:235–9.

Article  PubMed  CAS  Google Scholar 

Hinshaw A, Cares K, Thomas R, El-Baba M. Efficacy of infliximab biosimilar for maintenance therapy in pediatric inflammatory bowel disease following infliximab originator. JPGN Rep. 2022;3:e256.

Article  PubMed  PubMed Central  Google Scholar 

van Hoeve K, Dreesen E, Hoffman I, Van Assche G, Ferrante M, Gils A, et al. Efficacy, pharmacokinetics, and immunogenicity is not affected by switching from infliximab originator to a biosimilar in pediatric patients with inflammatory Bowel disease. Ther Drug Monit. 2019;41:317–24.

Article  PubMed  Google Scholar 

Kang B, Lee Y, Lee K, Choi YO, Choe YH. Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: a single-center prospective observational study. Inflamm Bowel Dis. 2018;24:607–16.

Article  PubMed  Google Scholar 

Sieczkowska J, Jarzębicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Preliminary Observ ECCOJC. 2016;10:127–32.

Article  CAS  Google Scholar 

Bergqvist V, Kadivar M, Molin D, Angelison L, Hammarlund P, Olin M, et al. Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease. Therap Adv Gastroenterol. 2018;11:175628481880124.

Article  Google Scholar 

Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221–8.

Article  PubMed  PubMed Central  Google Scholar 

Tuppin P, Rudant J, Constantinou P, Gastaldi-Ménager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Revue d’Épidémiologie et de Santé Publique. 2017;65:S149–67.

Article  PubMed  Google Scholar 

Roland N, Baricault B, Weill A, Bouillon K, Dray-Spira R, Duranteau L, et al. Association between doses of levonorgestrel intrauterine systems and subsequent use of psychotropic drugs in France. JAMA. 2023;329:257.

Article  PubMed  CAS  Google Scholar 

Kolla E, Weill A, Zaidan M, De Martin E, Colin De Verdiere S, Semenzato L, et al. COVID-19 hospitalization in solid organ transplant recipients on immunosuppressive therapy. JAMA Netw Open. 2023;6:2342006.

Article  Google Scholar 

Le Vu S, Bertrand M, Botton J, Jabagi MJ, Drouin J, Semenzato L, et al. Risk of guillain-barré syndrome following COVID-19 vaccines: a nationwide self-controlled case series study. Neurology. 2023;101:e2094-102.

Article  PubMed  PubMed Central  Google Scholar